Ballew Advisors’s AbbVie ABBV Stock Holding History

Ballew Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$459K	Buy	1,759 +6	+0.3%	+$1.29K	0.24%	80
2026 Q1	$372K	Buy	1,753 +4	+0.2%	+$887	0.21%	84
2025 Q4	$386K	Buy	1,749 +48	+3%	+$10.9K	0.22%	81
2025 Q3	$390K	Buy	1,701 +376	+28%	+$76.6K	0.22%	80
2025 Q2	$251K	Buy	1,325 +6	+0.5%	+$1.11K	0.15%	99
2025 Q1	$231K	Buy	+1,319	New	+$256K	0.15%	101
2024 Q4	–	Sell	-1,123	Closed	-$219K	–	105
2024 Q3	$219K	Buy	+1,123	New	+$210K	0.15%	100
2018 Q4	–	Sell	-521	Closed	-$42K	–	93
2018 Q3	$42K	Buy	521 +3	+0.6%	+$284	0.04%	172
2018 Q2	$48K	Buy	518 +3	+0.6%	+$293	0.05%	158
2018 Q1	$49K	Buy	+515	New	+$56.6K	0.04%	162

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ballew Advisors's ABBV Position: Q2 2026 in Review

Ballew Advisors increased its AbbVie (ABBV) stake by 0.34% in Q2 2026, buying an estimated $1.29K and bringing the position to 1,759 shares worth $459K. The position accounts for 0.24% of the portfolio, ranked #80.

Ballew Advisors first reported a position in ABBV in Q1 2018 and has held it in 10 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Ballew Advisors held 1,759 shares of AbbVie worth $459K as of Q2 2026.
Ballew Advisors bought 6 AbbVie shares in Q2 2026, an estimated $1.29K.
AbbVie made up 0.24% of Ballew Advisors's portfolio in Q2 2026, its #80 holding.
Ballew Advisors first reported a position in AbbVie in Q1 2018 and has held it in 10 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ballew Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.